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ABSTRACT
In chronic lymphocytic leukemia (CLL), mutation and loss of p53 and ATM 
abrogate DNA damage signalling and predict poorer response and shorter survival. 
We hypothesised that poly (ADP-ribose) polymerase (PARP) activity, which is crucial 
for repair of DNA breaks induced by oxidative stress or chemotherapy, may be an 
additional predictive biomarker and a target for therapy with PARP inhibitors.
We measured PARP activity in 109 patient-derived CLL samples, which varied 
widely (192 – 190052 pmol PAR/106 cells) compared to that seen in healthy volunteer 
lymphocytes (2451 – 7519 pmol PAR/106 cells). PARP activity was associated 
with PARP1 protein expression and endogenous PAR levels. PARP activity was not 
associated with p53 or ATM loss, Binet stage, IGHV mutational status or survival, 
but correlated with Bcl-2 and Rel A (an NF-kB subunit). Levels of 8-hydroxy-2’-
deoxyguanosine in DNA (a marker of oxidative damage) were not associated with PAR 
levels or PARP activity. The potent PARP inhibitor, talazoparib (BMN 673), inhibited 
CD40L-stimulated proliferation of CLL cells at nM concentrations, independently of 
Binet stage or p53/ATM function.
PARP activity is highly variable in CLL and correlates with stress-induced 
proteins. Proliferating CLL cells (including those with p53 or ATM loss) are highly 
sensitive to the PARP inhibitor talazoparib.
INTRODUCTION
B-cell chronic lymphocytic leukaemia (CLL) 
patients have a variable disease but the onset of molecular 
profiling has revolutionised our understanding of CLL, 
and identified recurrent mutations and novel targets 
that may be exploited therapeutically. Current treatment 
protocols have improved response rates for many patients 
[1] and newer approaches targeting B-cell receptor (BCR) 
signalling show great promise in clinical trials [2]. Despite 
these advances, CLL remains incurable, and since CLL 
patients are predominantly elderly, they cannot tolerate 
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aggressive therapies. The development of biomarkers to 
stratify subgroups of patients for personalised medicine is 
therefore crucial to achieve the best therapeutic outcomes 
for these patients.
Cytogenetic abnormalities including mutation 
and loss of p53 and ataxia telangiectasia mutated kinase 
(ATM) (del(17p) and del(11q) respectively) confer 
chemoresistance and are associated with poorer response 
and shorter overall survival [3, 4]. Both ATM and p53 
signal DNA double-strand breaks (DSB) with ATM 
also promoting their high-fidelity repair by homologous 
recombination repair (HRR). These phenotypes were 
recently found to impact on the newer kinase inhibitors 
that target BCR signalling. Although the mechanism 
of action of the BTK inhibitors is p53-independent, 
underlying genomic instability in patients with p53 and 
ATM loss can result in acquired mutations in the kinase, 
resulting in drug resistance [5]. 
 We reasoned that genomic instability arising 
from unresolved single-strand DNA breaks may also be 
important in response to DNA damaging therapy in CLL. 
Poly(ADP-ribose) polymerase-1 (PARP1) is activated by 
DNA strand breaks and is pivotal in the signalling to their 
repair [6]. Since PARP1 has a key role in the response 
to DNA damage, it is currently being pursued as a drug 
target in several clinical trials [7]. We co-developed the 
first clinically-used PARP inhibitor [8] for combination 
chemotherapy but subsequent studies identified the 
synthetic lethality of PARP inhibitor monotherapy in 
HRR-defective (HRD) tumours, notably those with BRCA 
mutations [9, 10]. Importantly, PARP1 is known to be part 
of the first line of defence against oxidative stress, which 
is increased in cancer and associated with poor prognosis 
in CLL [11]. 
In agreement with the known synthetic lethality of 
PARP inhibitors in HRD tumours, ATM-defective CLL 
can call be selectively targeted by the PARP inhibitor, 
olaparib [12]. A phase I/II clinical trial is investigating the 
use of olaparib in CLL patients stratified by ATM status 
(11q deletion or ATM mutation: ISRCTN34386131 http://
www.isrctn.com/ISRCTN34386131) and phase I studies 
of talazoparib have been undertaken in haematological 
malignancies (NCT01399840). 
A comprehensive analysis of PARP1 function 
in CLL is lacking. We previously observed that PARP 
activity was very high in a pilot cohort of CLL cases [13] 
and hypothesised that defects in DNA repair (e.g. loss 
of p53 or ATM function), response to oxidative stress or 
oncogene activation could lead to up-regulation of PARP1 
and greater reliance on PARP activity for survival of 
CLL cells. We hypothesised therefore that PARP activity 
could not only be a key determinant of patient sensitivity 
to chemotherapies that stimulate PARP activity, but 
also to PARP inhibitors themselves. Here, we analysed 
the expression and activity of PARP1 in a large cohort 
of patient-derived CLL cells (n = 109). We found that 
PARP activity was highly variable in CLL patients, and 
tended to be higher than PBMCs from healthy volunteers 
(HV). PARP activity and/or PARP1 protein levels were 
associated with levels of the antiapoptotic protein, Bcl2, 
and the DNA binding of the stress-induced transcription 
factor NF-kB subunit, RelA. PARP activity was not 
associated with ATM dysfunction or levels of oxidative 
DNA damage and the potent PARP inhibitor talazoparib 
inhibited the growth of patient derived CLL cells at low 
concentrations, even in cells with functional HRR.
RESULTS
PARP activity is more variable in CLL cells than 
in PBMCs from healthy volunteers
PARP activity and endogenous PAR levels in 
patient-derived CLL samples (109 and 90 samples, 
respectively) were more variable than in PBMCs from 
HV (n = 8, age 25-51, mean 37). In CLL samples there 
was an approximately 1,000-fold difference from highest 
to lowest (192- 190052, mean = 11968; median = 5615 
pmol PAR formed/106 cells, coefficient of variation = 
1.92) compared to PBMCs (3-fold variation) from HV 
(range = 2452 - 7519, mean = 4365; median = 3315 pmol 
PAR formed/106 cells, coefficient of variation = 0.47) 
(Figure 1A, left). Similarly, endogenous PAR levels were 
also highly variable ( > 4,000-fold) in CLL cells (0.7 - 
3090 pmol, mean = 110; median = 6.0 pmol PAR/106 
cells, coefficient of variation = 3.33) compared to HV 
lymphocytes (3.66 - 52.9 pmol mean = 13.8; median = 
8.8 pmol PAR/106 cells, coefficient of variation = 0.88) 
and there was a population of cells that had particularly 
high levels (Figure 1A, right). PARP activity significantly 
correlated with endogenous PAR levels (p = 0.01 r = 
0.27; Supplementary Figure S1). Variable PARP activity 
and endogenous PAR levels were observed across all 
cytogenetic groupings with no obvious relationship 
between PARP activity (Figure 1B) or endogenous PAR 
levels (Figure 1C) and cytogenetic abnormalities, and no 
obvious distinction between treated and untreated patients. 
Some patients’ CLL cells were sampled on more than one 
occasion from diagnosis through their disease course, 
and measurement of PARP activity did not reveal any 
particular trend in PARP activity over the course of disease 
(supplementary Figure S2). These data suggest that neither 
cytogenetics nor prior therapy influence PARP activity in 
CLL.
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Figure 1: PARP catalytic activity in CLL cells. PARP activity was determined by measuring the product (PAR) using a GCLP 
validated assay (n = 109 CLL cases). A. PARP activity (left) and endogenous PAR levels (right) in CLL cells and PBMCs from HV. Lines 
and error bars represent median and 25th/75th centiles. PARP activity B. and endogenous PAR levels C. in CLL cells is stratified by 
cytogenetic abnormalities from patients who had received (red bars) or not received (black bars) prior therapy. Samples are classified as 
either ‘del(13q)/none’ (patients with del(13q) and those who had no cytogenetic abnormalities), ‘12+’ (patients with trisomy 12), ‘del(11q)’, 
or del(17p)/p53(M) (loss and/or mutation of p53). All data are from duplicate determinations in a single assay.
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Cellular PARP activity and Bcl-2 levels are 
related to PARP1 levels and RelA DNA binding is 
associated with PARP activity
Since the variation in PARP activity did not 
correlate with cytogenetic abnormalities we investigated 
if it was dependent on differential expression of PARP1 
and measures of anti-apoptotic and stress signalling. Bcl2 
and PARP1 protein expression was analysed by Western 
blotting (Figure 2A). PARPa aactivity correlated with 
PARP1 protein levels (p = 0.046, Spearman’s rank (p = 
0.138 with Bonferroni correction)) (Figure 2B) although 
the relationship was not strong (r = 0.367). Interestingly, 
the levels of the anti-apoptotic protein, Bcl2, which is 
known to play a major role in CLL [14, 15] significantly 
correlated with PARP1 levels (p = 0.003, Spearman’s 
rank (p = 0.009 with Bonferroni correction)) and the 
Figure 2: PARP1 protein levels and activity in relation to Bcl2 expression and RelA DNA binding. A. Whole cell lysates 
were prepared from CLL cases (n = 30) and expression of PARP1 and Bcl2 was measured by Western blot (two blots shown) and quantified 
using chemiluminescence detection and interpolation from a standard curve generated by probing known concentrations of K562 whole 
cell lysates (5, 10, 20 and 40 µg, as shown) for PARP1 and Bcl2 (highlighted in black boxes): sample 35 (outlined on right) was evaluated 
in both blots with similar results. The correlation between PARP1 expression and PARP activity (n = 30) B. Bcl2 expression (n = 26) C. 
and nuclear NF-κB (RelA) (n = 27) D. was analysed. RelA binding was also correlated with PARP1 activity (n = 65) E.. All data are from 
single determinations.
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relationship was stronger (r = 0.562) (Figure 2C). PARP 
has been implicated in the apoptotic process; not only 
is it cleaved by caspases but PAR formation promotes 
apoptosis inducing factor release from the mitochondrion 
and nuclear translocation triggering caspase-independent 
apoptosis [16]. However, there was no correlation between 
PARP1 levels and RelA (a component of the stress-
activated pro-survival transcriptional activator protein 
complex NFkB) binding to DNA (Figure 2D). RelA DNA 
binding did correlate with PARP activity in the CLL 
samples (Figure 2E, n = 65; p = 0.045) but the relationship 
was weak (r = 0.25). 
Elevated PARP activity is not related to p53 or 
ATM function
Since the data on cytogenetic abnormalities in Figure 
1 may not definitively reflect p53 and ATM function, we 
analysed the distribution of PARP activity in 102 patients 
stratified according to their p53 status, including those 
cases that had TP53 mutation without del(17p) (n = 86 wild 
type (WT) and p53 mutant (M) n = 16) but there was still 
no significant correlation (p = 0.15, Mann Whitney, Figure 
3A). Similarly, we examined whether the functional status 
of ATM, a key player in HRR, had any relationship with 
PARP activity. Approximately 60% of del(11q) cases have 
fully functional ATM, and only those cases with biallelic 
loss of ATM (with mutation on the remaining allele) have 
non-functional ATM. Therefore, we stratified the del(11q) 
Figure 3: Elevated PARP activity in relation to p53 and ATM function, cytogenetics and disease status. PARP activity was 
examined in relation to p53 function (WT [n = 86] or loss or mutation [M, n = 16] A., and ATM function (F, ability to auto-phosphorylate 
(ser1981) and phosphorylate SMC-1, see materials & methods, n = 34) or dysfunction (NF n = 12) B.. Patients were grouped in terms of 
cytogenetic abnormalities to compare PARP activity C.. D. PARP activity in relation to disease status: progressive disease (n = 46), defined 
as Binet stage B or C, or non-progressive (n = 57), Binet stage A at the time of sample collection. Data are individual sample values (from 
duplicates in a single assay) with median line shown. 
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group according to ATM functional status, i.e. the ability 
to auto-phosphorylate (ser1981) and phosphorylate SMC-
1, (Supplementary figure S3). In the 46 cases evaluated, 
there was no difference in PARP activity between those 
with functional (n = 34) or non-functional (n = 12) 
ATM (p = 0.42) (Figure 3B, supplementary Table S2). 
Similarly, endogenous PAR levels did not correlate with 
p53 or ATM function (supplementary Figure S4A, S4B, 
Table S2). PARP activity was not significantly associated 
with any particular cytogenetic abnormality (del(13q) 
versus del(17p)/TP53, n = 98, p = 0.13 Mann Whitney; 
Figure 3C). Similarly, endogenous PAR levels were not 
associated with cytogenetic abnormalities, supplementary 
Figure S4C). PARP activity had a tendency to be higher 
in patients with progressive disease, defined as Binet 
stage B or C (n = 46), compared to those with non-
progressive disease, Binet stage A, (n = 57) but again, this 
was not significant (p = 0.08 Mann Whitney, Figure 3D). 
Endogenous PAR levels did not correlate with disease 
progression (n = 84;p = 0.47, supplementary Figure 
S4D). Neither PARP activity nor endogenous PAR levels 
were related to IGHV mutation status (p = 0.94 and 0.39, 
respectively), data not shown.
Figure 4: Oxidative DNA damage in relation to cytogenetic abnormalities, PARP activity and endogenous PAR levels. 
8-hydroxy-2’-deoxyguanosine (8-OHdG) levels, quantified by ELISA in 56 CLL samples in relation to cytogenetic abnormalities and prior 
therapy (red bars) or untreated (black bars) A.. PARP1 activity (B; n = 56) and endogenous PAR levels (C; n = 47) in relation to 8-OHdG 
levels. All data are from single determinations.
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PARP activity and endogenous PAR levels are not 
predictive of survival in CLL
Since PARP activity is a continuous variable, 
we used ROC curve survival analysis to examine the 
impact of PARP activity on patient outcome. Maximally 
stimulated PARP activity and basal PAR levels did not 
have clinically relevant discriminatory power using ROC 
curve survival analysis at 2.5 years and 5 years (30 and 60 
months) post-diagnosis (supplementary figure S7). AUC 
values of below 0.75 were deemed to be of no clinical 
significance [17] with relation to PARP as a prognostic 
marker in CLL. 
8-OHdG levels do not correlate with PARP 
activity, endogenous PAR levels, cytogenetic 
abnormalities, p53 functional status, or treatment 
status
PARP is activated by DNA breaks, with the most 
common endogenous cause of these breaks being oxidative 
stress/reactive oxygen species (ROS). 8-OHdG is the 
predominant form of ROS-induced DNA damage. ROS 
levels are reported to be higher in CLL and associated 
with poor prognosis [11]. Therefore, to determine if ROS-
induced DNA damage was associated with cytogenetic 
abnormalities or PARP activity, or if the endogenous PAR 
levels reflected the level of ongoing DNA damage, we 
measured 8-OHdG in DNA extracted from 56 treatment-
naïve or pre-treated CLL patient samples (Figure 4). 
In particular, we wanted to determine if the outlier 
population of cells with high endogenous PAR (observed 
in Figure 1A) was due to high levels of oxidative stress. 
There was no relationship between 8-OHdG levels and 
the cytogenetic groups or in response to prior therapy 
(Figure 4A), PARP activity (Figure 4B) or endogenous 
PAR (Figure 4C), implying that the highly variable PARP 
activity in CLL does not reflect levels of oxidative stress.
Talazoparib inhibits the growth of CLL cells 
irrespective of ATM and HRR status
By culturing CLL cells on an irradiated monolayer 
expressing the CD40 ligand (CD40L), CLL cells can be 
induced to proliferate, making growth inhibition studies 
possible [18], and pilot studies confirmed induction of 
proliferation (Supplementary Figure S5). PARP inhibitors 
are synthetically lethal to cells with HRR dysfunction and 
ATM is thought to function in the HRR pathway [12]. 
In initial studies using CLL samples from 4 patients, 
(including an ATM dysfunctional and a del11q case) 
proliferating CLL cells cultured on the CD40L-expressing 
cells for 72 hr were exposed to talazoparib (0- 10,000 nM) 
( Method 1). Cell counting over 96-168 hr, (i.e. 72 hr 
exposure) revealed a concentration-dependent suppression 
of cell growth (Figure 5A left panel) with GI
50
 values 
between 19 and > 1000 nM talazoparib (Table 1). It has 
been suggested that high PARP activity is associated with 
HRR defects [19], although our data do not indicate that 
ATM defects are associated with higher PARP activity 
(Figure 3B). To investigate if PARP activity was related to 
HRR status and hence sensitivity to talazoparib, 3 further 
CLL samples (193, 199 and 208) with high, medium or 
low PARP activity and low or high endogenous PAR levels 
(Table 1) were stimulated to proliferate on a CD40L-























175 Del(11q) B WT F 1105.1 5.14 0 994.0
191 Del(13q) A WT F 62676.3 8.9 0 19.39
200 Del(13q) A WT NF 3317.3 4.1 0.242 191.2
206 Del(13q) A WT - 3701.0 32.1 0 >1000
193 Del(13q) - WT - 3330.7 309.6 0.211 27.3
199 Del(17p)/p53 M C Del/M F 12403 3.4 0.169 30.6
208 Del(13q) A WT F 24252.8 416.2 0 25.6
Samples 175, 191, 200 and 206 were exposed to talazoparib using CD40L co-culture method 1, where cells were cultured 
in talazoparib containing media 72 – 168 hr post seeding. Samples 193, 199 and 208 which had pre-exposure to talazoparib 
(method 2) and were therefore cultured with drug for the full 168 hr time-course are marked in grey.
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Figure 5: Growth inhibition by potent PARP inhibitor, talazoparib in ATM dysfunctional and HRR functional CLL 
cells. A. Concentration response curves for CLL samples stimulated to proliferate on a CD40L feeder layer and treated with 0 – 1000 nM 
talazoparib. Left graph shows concentration response using method 1, right graph using method 2 (see supplementary Figure S6 for details 
of drug exposure). Curves are representative of change in cell numbers between 96 - 168 hr exposure. HRR status was determined after 144 
hr exposure to 1,000 nM talazoparib by measuring γH2AX immunofluorescence to confirm DNA replication fork collapse, and RAD51 to 
confirm HRR functionality. Example photomicrographs (x40) are shown in panel B, and data from at least 500 nuclei/treatment (analysed 
by image J) are shown in panel C (bold lines are median values).
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expressing layer, and exposed to talazoparib (0 nM - 
1,000 nM) after a 72 hr talazoparib pre-exposure period 
(method 2). Cell counts over the same 96-168 hr time-
period demonstrated a profound suppression of growth by 
all concentrations of talazoparib with GI
50
 values of < 25 
- 30 nM (Figure 5A right panel, supplementary figure S6). 
Although these data seem to imply that ATM dysfunction 
confers resistance to talazoparib, a direct comparison 
cannot be made between data from method 1 and 2 due to 
the differences in the pre-exposure period. However, using 
method 1, sample 200 (which had non-functional ATM) 
had a 10-fold higher GI
50 
value than sample 191 (which 
had functional ATM). 
To further determine whether sensitivity was a 
result of defective HRR, cells exposed to 1000 nM 
talazoparib or vehicle were harvested and HRR function 
determined by measuring γH2AX and RAD51 foci. A ≥2-
fold increase in γH2AX foci was taken as confirmation 
that stalled/collapsed replication forks and/or DSB had 
been generated. Cells were defined as HRR competent 
if a ≥2-fold increase in RAD51 foci was also observed 
as previously described [20, 21]. Samples 193 and 199 
generated analysable results. Both CLL samples were 
HRR competent (Figure 5B and 5C). Patient 208 also 
displayed an increase in RAD51 foci indicating HRR 
competence, however the staining was too poor to analyse 
fully (data not shown). This suggests that even HRR 
competent CLL cells are sensitive to talazoparib.
DISCUSSION
Here we show, for the first time, a comprehensive 
analysis of the activity and expression of PARP1 in a 
large cohort of CLL tumours. PARP activity was found 
to be highly variable among the 109 cases analysed 
ranging from 200-190,000 pmol PAR/106 CLL cells, 
i.e. almost 1,000-fold variation. B-cells are reported to 
have approximately 2-fold higher PARP1 protein levels 
compared to T cells [22], but some patients had values > 
10,000 pmol/106 cells, far higher than previously reported 
for normal PBMCs. By comparison, PARP activity was 
less variable in PBMCs from HVs, and although this was 
from a small cohort (n = 8) it was within the range seen 
in a separate HV cohort (n = 56) in our previous study 
(10 - 2,190 pmol PAR/106cells; [23]). In the CLL cohort 
studied here, although approximately 1/3 patients had 
higher PARP activity than HV, median PARP activity was 
not significantly different in CLL cases, largely due to the 
huge variation in activity in the cohort.
To understand the variation in PARP activity 
observed, we measured PARP1 protein levels and 
discovered that, although there was a significant 
correlation between protein levels and activity, the strength 
of the correlation was weak as observed previously [23]. 
This suggests that the activity of PARP1 is influenced 
by post-translational modification. To understand this 
modulation of PARP activity we examined associated 
clinical data. Treatment status (treatment-naïve as opposed 
to having received treatment), IGHV status, adverse 
cytogenetic abnormalities or Binet stage did not have a 
significant impact on the level of PARP activity. However, 
we noted that there was a trend for PARP activity to be 
higher in patients with Binet stage B or C and in patients 
with p53 defects (Figure 3). We therefore examined PARP 
activity in sequential samples taken from the same patient 
(Figure S2), but there was no particular trend in PARP 
activity over the course of disease.
We had hypothesised that PARP activity may be 
related to underlying genomic instability, (due to p53 or 
ATM loss), because such cells may be reliant on PARP 
function for repair of DNA damage. In fact, our data 
suggest that neither p53 nor ATM loss closely correlate 
with PARP function. In our cohort, 16/102 patients lacked 
p53 function, but neither PARP activity nor endogenous 
PAR levels were significantly related to p53 status. This 
indicates that in CLL PARP activity is not required in 
response to the genomic instability and compromised 
DNA damage signalling resulting from loss of p53. This 
contrasts somewhat with a recent publication [24] that 
found PARP1 expression was lower in CLL samples with 
mutated TP53 and unmutated IGHV, and that apoptosis 
positively correlated with PARP1 expression. However, in 
that study PARP1 protein levels and activity were only 
determined in a small subset of samples after irradiation 
and, because PARP activity is only partially dependent 
on its protein level and concordance between mRNA 
and protein levels is highly variable [24, 26], we believe 
determination of PARP function is a more robust indicator 
of the cellular phenotype.
Defects in HRR are known to confer sensitivity 
to PARP inhibitors due to the accumulation of SSB in 
PARP-inhibited cells that would normally be resolved at 
replication by HRR [27]. ATM promotes HRR, and lack 
of ATM has been shown to result in sensitivity to the 
PARP inhibitor, olaparib in replicating CLL cells [12]. 
We postulated that CLL cells lacking ATM might be more 
dependent on PARP and therefore have increased PARP 
activity. Since del(11q) status alone does not necessarily 
confer ATM loss (as mutation or loss of the second allele 
is needed for complete inactivation) we assessed ATM 
function in selected cases . In 12/46 cases with non-
functional ATM, PARP activity was similar to cases with 
functional ATM, suggesting that ATM dysfunction does 
not result in an increased reliance on PARP activity. This 
confirms a lack of association between HRR function and 
PARP activity previously observed in primary cultures of 
cells in ovarian cancer ascites [A Mukhopadhyay, PhD 
thesis, Newcastle University 2011]. 
To probe the role of ATM and HRR status further, 
and assess PARP as a therapeutic target in CLL, we 
analysed the effect the highly potent PARP inhibitor, 
talazoparib (cell-free IC
50
 = 0.57 nM, [27] on the 
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proliferation of CLL cells using the CD40L-stimulated 
co-culture model. Here, we used two different culture 
conditions to allow us to test different exposure times to 
study the effect of talazoparib on proliferating CLL cells, 
including the conditions that were previously used [12] 
and had enough material available to examine a sample 
which was confirmed as ATM non-functional (CLL 200, 
Figure 5 and supplementary figure S3) and another with 
confirmed p53 loss (CLL 199). We found that sensitivity 
to talazoparib was independent of the ATM functional 
status of the cells, in contrast to previous studies showing 
that ATM dysfunctional CLL cells were more sensitive to 
the PARP inhibitor, olaparib [12]. Duration of exposure 
to talazoparib at concentrations of 10 nM appears to be 
important to achieve high levels of cytotoxicity, since 
samples exposed for 168 hours versus 72 hours had lower 
GI
50
 values. A sub-population of cells appear capable of 
proliferation even at higher concentrations of talazoparib, 
and this may reflect an intrinsically resistant sub-
population in a heterogeneous population of CLL cells. 
Our previous studies indicated that a 30 min pulse with 
talazoparib reduced PARP activity in HV PBMCs cells 
with an IC
50
 of approximately 7±6 nM (James Murray, 
unpublished data) suggesting that PARP activity probably 
needs to be suppressed by > 50% for growth inhibition. In 
our studies the case with confirmed p53 loss (CLL 199) 
had similar sensitivity to talazoparib compared to cases 
with wild type p53. Since p53 loss remains the main 
indicator of refractory disease, these data present the 
exciting possibility that talazoparib is effective at reducing 
proliferation of CLL cells in this difficult-to-treat patient 
population. All of the samples tested had functional HRR, 
but this was not associated with resistance to talazoparib. 
Interestingly, using both method 1 and method 2 to 
evaluate talazoparib cytotoxicity, the cells with the highest 
PARP activity, CLL 208 (method 1) and 191 (method 2), 
were the most sensitive.
Since our data suggested that neither p53 nor ATM 
status were determinants of intrinsic PARP activity or 
sensitivity to PARP inhibition, we explored other factors 
that may alter PARP activity. Bcl-2 is an important pro-
survival protein, and a member of a family of proteins 
that dictate the balance between survival and apoptosis. In 
CLL, Bcl-2 is frequently highly expressed and associated 
with disease progression [15] and as such, is being 
explored as a target in current clinical trials for CLL and 
other malignancies [28]. We observed high expression 
of Bcl-2 in the subset of the cohort we analysed, and 
found that levels of Bcl-2 significantly correlated with 
PARP expression. Our results suggest that CLL cells 
may rely more on PARP function, or increase PARP 
function to promote repair and survival, and in parallel 
upregulate pro-survival signalling, including Bcl-2 to 
inhibit apoptosis. In agreement with this, we also found 
that levels of the NF-κB subunit, RelA, were associated 
with high PARP activity. NF-κB induces transcription of a 
large repertoire of stress-response genes in CLL, including 
the anti-apoptotic proteins Bcl-2 and Mcl-1 [29], allowing 
us to speculate that stress-induced activation of PARP, and 
NF-κB in CLL cells occurs as a mechanism of protecting 
CLL cells from damage.
Endogenous PAR levels varied widely between 
samples. CLL cells are known to have high levels of 
reactive oxygen species [11], resulting in increased 
8-OHdG DNA lesions that activate PARP. However 
measurement of 8-OHdG in DNA extracted from a subset 
of our cohort of CLL samples with high, intermediate 
or low PAR levels did not reveal a relationship between 
either endogenous PAR levels or PARP activity and levels 
of 8-OHdG. It should be recognised that the levels of 
8-OHdG represent a balance between induction of DNA 
damage and its repair, and PAR levels reflect both ongoing 
synthesis by PARP and degradation by PARG. Therefore, 
although one might expect high levels of 8-OHdG to 
be associated with high levels of endogenous PAR, it is 
possible that in cases where high PAR levels were found 
in CLL samples with low 8-OHdG, this may have reflected 
high rates of repair, conversely high levels of 8-OHdG 
in the absence of high PAR may reflect reduced rates of 
repair and/or high PARG activity. 
We wanted to determine whether PARP activity 
had any impact on outcome in our cohort. Preliminary 
analysis using median cut-off values suggested that high 
PARP activity was associated with poorer overall survival 
(OS) [13], however, since PARP activity is a continuous 
variable, we used ROC analysis to more accurately 
analyse effects on outcome. We found no association with 
PARP activity and survival, which is in agreement with 
our analysis of other clinical correlates such as cytogenetic 
abnormalities and disease progression, where we found 
that PARP activity was not strongly linked to clinical 
outcome.
In conclusion, our data suggest that neither PARP1 
expression nor activity correlate strongly with adverse 
cytogenetic abnormalities, p53 or ATM function or stage 
of disease, but it may be associated with anti-apoptotic 
proteins. However, encouragingly, our data show that, in 
an albeit limited number of ex vivo cultures, CLL cells 
were sensitive to talazoparib cytotoxicity independent of 
their p53, ATM or HRR status, confirming that PARP is a 
therapeutic target in CLL.
MATERIALS AND METHODS
Sample collection and processing
This study was approved by the UK NHS 
Research Ethics Service, and patient samples are part 
of the Newcastle Haematology Biobank http://www.
ncl.ac.uk/nbb/collections/nhb. Patient information is 
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described in supplementary Table S1. Following written 
informed consent, patients provided peripheral blood 
samples which were transported to the laboratory and 
processed immediately using Lymphoprep (Axis Shield, 
Cambridgeshire, UK). Sample collection, processing and 
storage were carried out in accordance with the regulations 
of the Human Tissue Act 2004 (UK) and local guidelines. 
Binet staging refers to the patient status at the time of 
sample collection. All chemicals were obtained from 
Sigma Aldrich (UK) unless otherwise stated.
Cytogenetic analyses
Interphase FISH and a multiple ligation dependent 
probe assay were used to determine cytogenetic 
abnormalities as previously described [30]. CLL cell 
DNA was extracted from 5 x 106 lymphocytes using a 
QIAmp DNA blood mini kit according to manufacturer’s 
instructions (Qiagen, UK). TP53 mutational status was 
determined by targeted next generation sequencing (details 
to be published separately) covering all coding exons (2-
11) using a ROCHE 454 GS-FLX platform (performed by 
NewGene, UK, http://www.newgene.org.uk). 
NF-κB DNA binding activity and expression
NF-κB activity was quantified in nuclear extracts 
using the Trans-AM NF-кB family Transcription Factor 
Assay ELISA Kit (Active Motif, Rixensart, Belgium). A 
standard curve (2 Gy-treated MDA-MB-231 cells) was 
used to calculate arbitrary units (AU) per µg of nuclear 
extract from the standard curve. 
Determination of PARP expression and activity
Whole-cell extracts were prepared using 
PhosphosafeTM Extraction Reagent (Novagen), and 
proteins separated using Criterion XT 3-8% Tris-
acetate (v/v) denaturing polyacrylamide gels (Bio-Rad), 
transferred onto Hybond C membrane (Amersham) and 
probed with anti-PARP-1 primary antibody (C2-10, 
Trevigen, Gaithersburg, MD, USA) then anti-mouse HRP-
linked secondary antibodies (Cell Signaling Technology) 
and ECL reagent (Amersham) detection. Quantification 
was performed using a Fuji LAS-3000 luminescent 
image analyzer system (Raytek, Sheffield, UK). PARP 
activity was determined in 103 digitonin-permeabilised 
cells (CLL or HV PBMCs) by immunoblotting for the 
product, PAR, with anti-PAR 10H Ab, following maximal 
stimulation with a palindromic DS oligonucleotide 
(5′-CGGAATTCCG-3′; Invitrogen, Paisley, UK 10 µg/
ml final concentration) in the presence of excess NAD+ 
(350 μM) using a GCLP (Good clinical laboratory 
practise)-validated assay as previously described [23]. 
CLL cells that had been stored at -80°C were thawed on 
ice and washed in PBS prior to assay. Endogenous PAR 
levels were measured in unreacted (i.e. in the absence 
of oligonucleotide or NAD+) cells. Because endogenous 
PAR levels were low, the maximum number possible were 
loaded, ranging from 4x103 to 2.5x105 permeabilised cells. 
Samples were assayed in duplicate, with PARP activity 
represented as mean recalculated PAR (pmol/106 cells). 
Determination of ATM function
CLL cells were treated with ionizing radiation (IR, 5 
Gy, Gulmay Medical Xstrahl RS320 X-irradiator (Gulmay 
Medical, Chertsey, UK). 45 minutes after IR treatment, 
cell lysates were prepared as described above and western 
blots were probed with antibodies to ATM (Abcam, 
Cambridge, UK), and (where possible) SMC1 (Millipore, 
MA, USA) and ATM-specific phosphorylation targets; 
pATM (ser1981) and pSMC1 (ser 966) (Cambridge 
Bioscience, Cambridge UK). Samples showing clear 
phosphorylation of ATM (ser1918) and SMC1 (ser966) 
following IR treatment were deemed ATM functional [4].
Measurement of Bcl-2 levels
Levels of Bcl-2 were determined in CLL cell lysates, 
prepared as described above, by Western Blotting using an 
anti-Bcl-2 antibody (sc-509 Santa Cruz), B-actin (Sigma 
A4700) and anti-mouse secondary antibody as described 
above.
Oxidative DNA damage ELISA
Detection and quantitation of 8-hydroxy-2’-
deoxyguanosine (8-OHdG) in DNA was carried out 
using the 8-oxo-dG ELISA kit II (4380-096-K, Trevigen, 
Maryland USA). The assay was carried out according to 
manufacturer’s protocol, with the exception of altering 
the standard curve range from 25 nM - 0.39 nM, to 
accommodate for lower 8-OHdG levels. 8-OHdG values 
were interpolated from standard curves, which were 
generated as per manufacturer’s instructions. The final 
8-OHdG values represent the amount of 8-OHdG (nM) 
per µg DNA. 
Growth inhibition by talazoparib of CLL cells 
cultured on CD40L-expressing cells
CD40L (or non-transfected cells, NTL) cells were 
seeded into 24-well plates (3x105 cells/ml) in RPMI 
medium containing 10% heat-inactivated foetal calf 
serum, 2 mM L-glutamine and 1% penicillin/ streptomycin 
and allowed to adhere. The cells were irradiated (75 Gy) 
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to prevent proliferation and incubated at 37oC overnight. 
CLL cells were thawed and resuspended at a density of 
2 x 107 cells/mL in RPMI supplemented with 10 ng/mL 
human interleukin-4. Cells were then seeded onto the 
monolayer at a density of 1x107 per well and incubated at 
37⁰C. Cells were monitored and began to proliferate after 
approximately 72 hours. 
After 72 hours, cells from duplicate wells were 
counted as a pre-treatment control. In order to determine 
optimal conditions, experiments were carried out in two 
ways. Initially (samples 175, 191, 200 and 206), CLL 
cells were co-cultured with CD40L-expressing cells for 
96 hours before being re-seeded onto a fresh feeder layer 
in culture medium containing talazoparib (provided by 
BioMarin Pharmaceutical Inc.) for a further 72 hours 
(‘method 1’). In subsequent experiments (samples 193, 
199, 208), 72 hour-cultured CLL cells were transferred 
onto fresh feeder layers in medium containing talazoparib. 
Drug-containing medium was replenished with fresh 
medium containing the same concentration of talazoparib 
after 72 hours and cells were counted at 24 hour intervals 
thereafter. Response to drug was measured for the last 
72hr (between 96 - 168 hours drug exposure, ‘method 2’). 
In both instances cell counts (Coulter counter, threshold 
set at 5-12 µm: Beckman Coulter, High Wycombe, UK) 
were plotted (a) against time and (b) as a concentration-
dependent response curve generated from the cell counts 
at the terminal 72 hr exposure period as a % of the vehicle 
control. 
HRR assay
Cells from the CD40L-stimulated cultures that 
had been treated with vehicle or 1000 nM talazoparib 
(method 2) were harvested after 144 hours and 1x104 
cells/ml cytospun onto microscope slides (Shandon 
Cytospin 2 centrifuge). Slides were dried, washed 2x in 
PBS, fixed in cold methanol and stored at -20⁰C. Slides 
were probed for γH2AX and RAD51 foci as described 
previously (16) using anti-phospho-Histone H2A.X 
(Ser139) (clone JBW301, Merck Millipore, Watford, 
UK), anti-RAD51 antibody (PC130 Calbiochem, Merk 
Millipore, Watford, UK) and secondary antibodies Alexa 
Fluor 546 Goat anti-mouse and Alexa Fluor 488 Goat 
anti-rabbit antibodies (Invitrogen, Life Technologies, 
Paisley, UK). Coverslips were mounted over the cells in 
media containing 4’,6-diamidino-2-phenylindole (DAPI) 
(Vectashield, Peterborough, UK). The number of γH2AX 
and RAD51 foci was analysed in > 500 cells per condition 
using ImageJ software with an in-house spot-counting 
macro [31].
Statistical analysis
As the data do not have Gaussian distributions, 
Mann Whitney tests, Kruskal Wallis tests or Spearman 
rank correlations were performed as indicated in results 
using GraphPad Prism software (http://www.graphpad.
com). 
Receiver operating characteristic (ROC) curve 
survival analysis was performed to assess the predictive 
accuracy of PARP activity at 2.5 and 5 years (30 and 60 
months), [32]. The method uses time-dependent sensitivity, 
specificity, and associated ROC curves to characterize the 
predictive accuracy of a continuous marker, when the 
outcome is a censored survival time. The area under the 
ROC curve (AUC) was determined using the true positive 
(TP) and false positive (FP) rate, with an AUC value 
below 0.75 deemed as having no clinical value. Analysis 
was carried out in R using the risksetAUC function, part 
of the risksetROC library R package version 1.0.3, URL: 
http://CRAN.R-project.org/package = risksetROC). [33]
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